Final results of weekly (w) neoadjuvant carboplatin (Cp) added to paclitaxel (P) followed by epirubicin (E) and cyclophosphamide (C) in triple negative breast cancer (TNBC) patients (pts): A BSMO breast cancer task force phase II study

Authors :: Fontaine, Christel
Cappoen, Nadia
Renard, Vincent
Van den Bulck, Heidi
Vuylsteke, Peter
Glorieux, Philippe
Dopchie, Catherine
Decoster, Lore
De Grève, Jacques
Awada, Ahmed
Wildiers, Hans
Clinical sciences
Medical Oncology
Laboratory of Molecular and Medical Oncology
Faculty of Medicine and Pharmacy
Publication Year :: 2018
Publisher :: American Association for Cancer Research Inc., 2018.

Tools